Connect Biopharma Holdings logo

CNTB - Connect Biopharma Holdings News Story

$22.1 0.1  0.5%

Last Trade - 28/07/21

Sector
Healthcare
Size
Mid Cap
Market Cap £884.3m
Enterprise Value £1.11bn
Revenue £n/a
Position in Universe 2686th / 7000

Connect Biopharma to Participate at the Jefferies Virtual Healthcare Conference

Wed 26th May, 2021 1:00pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210526:nGNX2NRgl7&default-theme=true


SAN DIEGO and TAICANG, SUZHOU, China, May 26, 2021 (GLOBE NEWSWIRE) -- Connect
Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the
“Company”), a global clinical-stage biopharmaceutical company dedicated to
improving the lives of patients with chronic inflammatory diseases through the
development of therapies derived from T cell-driven research, today announced
that Dr. Zheng Wei, Co-Founder & CEO of Connect Biopharma, will participate in
a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday,
June 2, 2021 at 10:00 am ET.

A live webcast of this fireside chat will be available on the Company’s
Investor Relations page accessible here:
https://investors.connectbiopharm.com/. A replay will be available on the
Company’s website following the event.

About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited is a global clinical-stage
biopharmaceutical company dedicated to improving the lives of patients living
with chronic inflammatory diseases through the development of therapies
derived from our T cell-driven research.

Our lead product candidate, CBP-201, is an antibody designed to target
interleukin-4 receptor alpha (IL-4Rα) and is currently being evaluated in
clinical trials for the treatment of atopic dermatitis (AD) and asthma and in
development for chronic rhinosinusitis with nasal polyps (CRSwNP). Our second
lead product candidate is CBP-307, a modulator of a T cell receptor known as
sphingosine 1-phosphate receptor 1 (S1P1) that is in development for the
treatment of ulcerative colitis (UC) and Crohn’s disease (CD). Furthermore,
we are developing CBP-174, a peripherally restricted antagonist of histamine
receptor 3, for the treatment of pruritus associated with skin inflammation.

With headquarters in China, additional operations in the United States and
Australia, and clinical development activities in those geographies as well as
Europe, Connect Biopharma is building a rich global pipeline of internally
designed, wholly owned small molecules and antibodies targeting several
aspects of T cell biology. For additional information about Connect Biopharma,
please visit our website at www.connectbiopharm.com.

IR/PR CONTACTS: 
Lazar FINN Partners 
David Carey (IR) 
T: +1-(212) 867-1768
david.carey@finnpartners.com

Erich Sandoval (Media)
 +1-(646) 871-8482 or +1-(917) 497-2867
erich.sandoval@finnpartners.com

Corporate Contacts:
info@connectpharm.com



(https://www.globenewswire.com/NewsRoom/AttachmentNg/3d9bee1e-db67-4fcf-b235-81ccd9eb6666)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.